Grand City Properties S.A.

  • WKN: A1JXCV
  • ISIN: LU0775917882
  • Land: Großherzogtum Luxemburg

Nachricht vom 04.10.2021 | 11:14

Grand City Properties S.A.: Release of a capital market information

Grand City Properties S.A. (IRSH)
04-Oct-2021 / 11:14 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 29 Interim Announcement

In the period from 27 September 2021 up to and including 1 October 2021, Grand City Properties S.A. bought back a total of 560,872 shares of Grand City Properties S.A. under the Share Buy-Back Programme 2021; on 15 March 2021, Grand City Properties S.A. disclosed pursuant to Art. 2 Sec. 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on 16 March 2021.

The overall volume of the shares bought back daily and the daily volume-weighted average stock market prices of the shares are as follows:

Date Aggregate volume Weighted average price (EUR)
27.09.2021 108,704 22.68280
28.09.2021 113,063 21.98459
29.09.2021 104,951 21.92307
30.09.2021 115,149 21.73979
01.10.2021 119,005 21.74015
In total 560,872 22.00628
 

The purchase of the Grand City Properties S.A. shares was carried out by a bank commissioned by Grand City Properties S.A. and exclusively via the Frankfurt Stock Exchange (XETRA trading).

More detailed information pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available on the internet at https://www.grandcityproperties.com/investor-relations/equity/share-buy-back/

Berlin, 4 October 2021

Grand City Properties S.A.
Board of Directors




show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021